Clinical Focus
Neurotrition targets three neurobiologically defined subclinical states — each representing a validated intervention window before irreversible clinical progression.
The prodromal stage between normal age-related cognitive change and diagnosable Alzheimer's disease — characterized by objective cognitive decline without functional impairment. The largest undertreated pre-clinical window before irreversible neurodegeneration.
Cholinergic precursor supply via targeted amino acids and lipids, neurotrophic upregulation through plant extracts with documented NGF/BDNF activity, mitochondrial cofactor restoration, and anti-neuroinflammatory support.
A neurobiologically measurable syndrome of persistent fatigue, cognitive impairment ('brain fog'), and autonomic dysregulation following viral insult. Characterized by mitochondrial dysfunction, immune dysregulation, and CNS hypometabolism — with no approved pharmacological treatment.
Mitochondrial electron chain cofactor restoration via vitaminoids and vitamins, anti-neuroinflammatory compounds, HPA-axis normalisation via adaptogenic plant extracts, circadian rhythm support, and antioxidant network restoration.
Chronic occupational stress-induced neurobiological deterioration — beyond psychological exhaustion. Measurable structural changes in prefrontal cortex and hippocampus, dopaminergic pathway exhaustion, and sustained HPA-axis dysregulation precede and outlast subjective burnout resolution.
Catecholaminergic precursor restoration via targeted amino acids and cofactors, HPA-axis normalisation through adaptogenic extracts and phospholipids, neuroprotection against glucocorticoid neurotoxicity, and prefrontal circuit support.